409 related articles for article (PubMed ID: 25294187)
1. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Puzanov I; Sosman J; Santoro A; Saif MW; Goff L; Dy GK; Zucali P; Means-Powell JA; Ma WW; Simonelli M; Martell R; Chai F; Lamar M; Savage RE; Schwartz B; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):159-68. PubMed ID: 25294187
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors.
Okusaka T; Aramaki T; Inaba Y; Nakamura S; Morimoto M; Moriguchi M; Sato T; Ikawa Y; Ikeda M; Furuse J
Cancer Sci; 2015 May; 106(5):611-7. PubMed ID: 25711511
[TBL] [Abstract][Full Text] [Related]
4. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
[TBL] [Abstract][Full Text] [Related]
6. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
7. The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
Yamamoto N; Murakami H; Nishina T; Hirashima T; Sugio K; Muro K; Takahashi T; Naito T; Yasui H; Akinaga S; Koh Y; Boku N
Ann Oncol; 2013 Jun; 24(6):1653-9. PubMed ID: 23413279
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
Pant S; Patel M; Kurkjian C; Hemphill B; Flores M; Thompson D; Bendell J
Cancer Invest; 2017 Aug; 35(7):463-472. PubMed ID: 28662341
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Yamamoto N; Murakami H; Hayashi H; Fujisaka Y; Hirashima T; Takeda K; Satouchi M; Miyoshi K; Akinaga S; Takahashi T; Nakagawa K
Br J Cancer; 2013 Nov; 109(11):2803-9. PubMed ID: 24169346
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Dasari A; Gore L; Messersmith WA; Diab S; Jimeno A; Weekes CD; Lewis KD; Drabkin HA; Flaig TW; Camidge DR
Invest New Drugs; 2013 Feb; 31(1):115-25. PubMed ID: 22415798
[TBL] [Abstract][Full Text] [Related]
12. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors.
Maguire WF; Schmitz JC; Scemama J; Czambel K; Lin Y; Green AG; Wu S; Lin H; Puhalla S; Rhee J; Stoller R; Tawbi H; Lee JJ; Wright JJ; Beumer JH; Chu E; Appleman LJ;
Cancer Chemother Pharmacol; 2021 Oct; 88(4):643-654. PubMed ID: 34164713
[TBL] [Abstract][Full Text] [Related]
15. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.
Pant S; Saleh M; Bendell J; Infante JR; Jones S; Kurkjian CD; Moore KM; Kazakin J; Abbadessa G; Wang Y; Chen Y; Schwartz B; Camacho LH
Ann Oncol; 2014 Jul; 25(7):1416-1421. PubMed ID: 24737778
[TBL] [Abstract][Full Text] [Related]
16. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
17. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Adjei AA; Richards DA; El-Khoueiry A; Braiteh F; Becerra CH; Stephenson JJ; Hezel AF; Sherman M; Garbo L; Leffingwell DP; Iverson C; Miner JN; Shen Z; Yeh LT; Gunawan S; Wilson DM; Manhard KJ; Rajagopalan P; Krissel H; Clendeninn NJ
Clin Cancer Res; 2016 May; 22(10):2368-76. PubMed ID: 26644411
[TBL] [Abstract][Full Text] [Related]
18. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
[TBL] [Abstract][Full Text] [Related]
19. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors.
Liu SV; Groshen SG; Kelly K; Reckamp KL; Belani C; Synold TW; Goldkorn A; Gitlitz BJ; Cristea MC; Gong IY; Semrad TJ; Xu Y; Xu T; Koczywas M; Gandara DR; Newman EM
Cancer Chemother Pharmacol; 2018 Oct; 82(4):723-732. PubMed ID: 30128950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]